NCIt definition : A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory
human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, finotonlimab
targets, binds to, and inhibits PD-1 and its downstream signaling pathways. This may
restore immune functions through the activation of T-cells and T-cell-mediated immune
responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin
superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively
regulates T-cell activation and effector function when activated by its ligands programmed
cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion
from host immunity.;
UNII : 533Z4G2286;
CAS number : 2350298-85-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2350298-85-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;